Printer Friendly

ACRIN TRIAL EVALUATES IMAGING FOR STAGING CERVICAL CANCER.

A new study conducted by the American College of Radiology Imaging Network (ACRIN(r)) and the Gynecologic Oncology Group (GOG) is now underway to evaluate the ability of positron emission tomography (PET)/computed tomography (CT) with Fluorodeoxyglucose (FDG-PET/CT) and MRI with the contrast agent Combidex (ferumoxtran-10) to identify pelvic and abdominal lymph node metastases in patients with locoregionally advanced cervical cancer.

According to study investigators, FDG-PET/CT and Combidex MRI offer promise for finding cancers that may presently go undiagnosed. "Currently, we try to diagnose lymph node metastases by size. This method has low specificity and low sensitivity," said ACRIN principal investigator for the trial, Mostafa Atri, M.D., of the University Health Network/Mount Sinai Hospital at the University of Toronto, Canada. "MRI with Combidex works differently. The contrast agent is absorbed by normal nodes, but not by the component of lymph node infiltrated by cancer. We see the cancer as defects in the lymph node. For PET, metastases appear as increased activity."

Approximately 10 ACRIN-approved sites will work in collaboration with a GOG member institution to accrue 325 participants within three years. All participants will undergo lymph node sampling to determine the accuracy of the imaging exams. Michael Gold, MD, of the University of Oklahoma, is the GOG study chair.

"Both imaging modalities can also be used with other cancers. Knowing the involvement of lymph nodes is important for the treatment of all cancer patients. If this study shows these modalities work for cervical cancer in a multicenter trial, it could lead to future research that would benefit many different cancer patients," said Atri.

Please visit www.acrin.org/6671_protocol.html for more information on this trial.

The American College of Radiology Imaging Network (ACRIN) is a National Cancer Institute Clinical Trials Cooperative Group. It is made up of investigators from over 100 academic and community-based medical facilities in the United States and several international institutions. ACRIN's mission is to develop information, through clinical trials of diagnostic imaging and image-guided therapeutic procedures, that will result in: 1) the earlier diagnosis of cancer, 2) allaying the concerns of those who do not have cancer, and 3) improved quality and increased length of life for cancer patients.

For more information, visit http://www.acrin.org or call 703/648-8936 or 800/227-5463, ext. 4936.

The American College of Radiology (ACR) is a national professional organization serving more than 32,000 diagnostic radiologists, radiation oncologists, interventional radiologists, nuclear medicine physicians and medical physicists, with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

For more information, visit http://www.acr.org.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Imaging Update
Date:Nov 1, 2007
Words:438
Previous Article:BANK UP SHOWS GROWTH IN CORPORATE CAPTURE BIZ.
Next Article:ZIEHM IMAGING/BRAINLAB TO DEVELOP 3D IMAGING/CAS.
Topics:


Related Articles
Genetic cause for some cervical cancers.
New biomarker for cervical cancer.
Selected ongoing clinical trials. (*) (Featured Cme Topic: Female Patient).
Gynecologic cancers & women's health.
Evaluating human papillomavirus vaccination programs.
Human papillomavirus and cervical cancer.
The Food and Drug Administration approves the HPV vaccine.
Cervarix for protection against cervical cancer.
Cancer of the cervix remains a very common female cancer in South Africa.
HOLOGIC DOES 3-YEAR ANALYSIS OF MAMMOSITE RADIATION THERAPY.

Terms of use | Copyright © 2015 Farlex, Inc. | Feedback | For webmasters